Back to top

Image: Bigstock

Can Blue Buffalo Pet (BUFF) Run Higher on Strong Earnings Estimate Revisions?

Read MoreHide Full Article

Blue Buffalo Pet Products, Inc. (BUFF - Free Report) , which develops, produces, markets and sells pet food, could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on BUFF’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Blue
Buffalo Pet could be a solid choice for investors.

Current Quarter Estimates for BUFF

In the past 30 days, two estimates have gone higher for Blue Buffalo Pet while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 28 cents a share 30 days ago, to 29 cents today, a move of 3.6%.

Current Year Estimates for BUFF

Meanwhile, Blue Buffalo Pet current year figures are also looking quite promising, with four estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, increasing from $1.07 per share 30 days ago to $1.16 per share today, an increase of 8.4%.

Blue Buffalo Pet Products, Inc. Price and Consensus

Bottom Line

The stock has also started to move higher lately, adding 16.8% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #2 (Buy) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

Published in